Assertio (ASRT) Q4 2025 earnings summary

Executive summary

• ROLVEDON identified as the primary long-term growth driver, with integration and operational efficiencies completed in Q4 2025 and a focus on maximizing its commercial potential through 2039 IP protection.

• Strategic shift away from acquiring on-market specialty products due to increased competition and pricing, with future business development focused on assets that leverage the existing oncology commercial platform.

• Commercial infrastructure is robust, targeting community oncology clinics, with ongoing enhancements to support further penetration and new product launches.

• Leadership emphasizes disciplined capital allocation, ongoing evaluation of asset divestiture, and openness to business combinations or licensing opportunities.

• FY2025 net product sales and adjusted EBITDA exceeded guidance, driven by strong performance in core assets and disciplined capital allocation.

Financial highlights

• FY2025 net product sales reached $117.1 million, slightly down from $120.8 million in 2024, with ROLVEDON sales up to $68.2 million and SYMPAZAN sales up to $11.3 million year-over-year.

• Gross margin improved to 75% in Q4 2025 from 61% in Q4 2024, and to 70% for full year 2025 from 68% in 2024, mainly due to product mix and reduced inventory write-downs.

• Adjusted EBITDA for FY2025 was $22.7 million, up from $18.3 million in 2024, reflecting lower SG&A expenses and improved gross margin.

• FY2025 net loss widened to $30.4 million from $21.6 million in 2024, with diluted net loss per share at $(4.74) versus $(3.40) prior year.

• Cash and equivalents at year-end were $63.4 million, down from $93.4 million at Q3 2025 and $100.1 million at year-end 2024, reflecting working capital changes and divestment cash transfer.

Outlook and guidance

• FY2026 net product sales expected between $110 million–$125 million and adjusted EBITDA between $28 million–$40 million, reflecting expected ROLVEDON growth offsetting declines in legacy assets.

• ROLVEDON sales expected to normalize and accelerate from Q2 2026, with no anticipated channel inventory build and new label launch.

• Indocin sales expected to decline in 2026 due to increased generic competition.

• Long-term ROLVEDON potential seen above $100 million in annual sales, with optimism for further growth.